CLAIMS

- Oligonucleotide for the specific identification of Staphylococci species which nucleotide sequence has between 15 and 45 base pairs, preferably between 15 and 25 base pairs, and which presents more than 60% homology with the "consensus" femA nucleotide sequence (CNS) of Fig. 3.
- 2. Oligonucleotide according to claim 1 for the specific identification of Staphylococci species, which nucleotide sequence has between 15 and 45 base pairs, preferably between 17 and 25 base pairs, and which presents more than 70% homology with the "consensus" femA nucleotide sequence (CNS) of Fig. 3.
- 3. Oligonucleotide according to claim 1 or 2

  15 for the specific identification of Staphylococci species,
  which nucleotide sequence has between 15 and 45 base pairs,
  preferably between 17 and 25 base pairs, and which presents
  more than 80% homology with the "consensus" femA nucleotide
  sequence (CNS) of Fig. 3.
- 20
  4. Oligonucleotide according to any of the claims 1 to 3 for the specific identification of Staphylococci species, which nucleotide sequence has between 15 and 45 base pairs, preferably between 17 and 25 base pairs, and which presents more than 90% homology with the "consensus" femA nucleotide sequence (CNS) of Fig. 3.
  - 5. Oligonucleotide according to any of the preceding claims, which is selected from the group consisting of the following nucleotide sequences:
  - ANAATGAANTTTACNAATTTNACNGCNANAGANTT
- 30 and more particularly TAATGAAGTTTACAAAATTT or TAATGAAGTTTACNAAATTT

- ATGNCNNANAGNCATTTNACNCANA and more particularly TGCCATATAGTCATTTACGC
- TAGTNGGNATNAANAANNATAANGANGTNATTGC
- GTNCCNGTNATGAAANTNTTNAANTANTTTTATTC
- 5 AATGCNGGNNANGATTGG
  - GNAANNGNAANACNAAAAAGTNNANAANAATGGNGTNAAAGT
    and more particularly AAAAAGTTCAAAAAATGG and
    AAAAAGTACAAAAAATGG
  - AAGANGANNTNCCNATNTTNNGNTCATTNATGGANGATAC
- 10 TATATNNANTTTGATGANTA
  - AANGANATNGANAAANGNCCNGANAANAAAAA

    and more particularly AAAGATATTGAAAAACGA,

    AAAGATATTGAAAAGAGACC, AAAGATATCGAGAAAGAC and

    AAAGACATCGACAAGCGT.
- 15 ANCATGGNAANGAATTACCNAT

  and more particularly GAACATGGTAATGAATTAC
  - AATCCNTNTGAAGTNGTNTANTANGCNGGTGG
  - AGNTATGCNNTNCAATGGNNNATGATTAANTATGC
  - TTTANNGANGANGCNGAAGATGNNGGNGTNNTNAANTTNAAAAA
- 20 and more particularly TTTACTGAAGATGCTGAAGA
  - GTTGGNGANTTNNTNAAACC
     and more particularly GTTGGTGACTTTATTAAACC
  - ATGAAATTTACAGAGTTAA
- 6. Oligonucleotide for the specific identification of Staphylococci species which nucleotide sequence has between 15 and 350 base pairs, preferably between 17 and 250 base pairs, and which presents less than 50% homology with the "consensus" femA nucleotide sequence (CNS) of Fig. 3.
- 7. Oligonucleotide according to claim 6 for the specific identification of Staphylococci species which nucleotide sequence has between 15 and 350 base pairs,

preferably between 17 and 250 base pairs, and which presents less than 40% homology with the "consensus" femA nucleotide sequence (CNS) of Fig. 3.

- 8. Oligonucleotide according to claim 6 or 7 for the specific identification of Staphylococci species which nucleotide sequence has between 15 and 350 base pairs, preferably between 17 and 250 base pairs, and which presents less than 30% homology with the "consensus" femA nucleotide sequence (CNS) of Fig. 3.
- 9. Oligonucleotide according to any of the claims 6 to 8 for the specific identification of staphylococci species which nucleotide sequence has between 15 and 350 base pairs, preferably between 17 and 250 base pairs, and which presents less than 20% homology with the "consensus" femA nucleotide sequence (CNS) of Fig. 3.
  - 10. Oligonucleotide according to claim 6, being a primer which nucleotide sequence has between 15 and 45 base pairs, preferably between 17 and 25 base pairs.
- 11. Oligonucleotide according to claim 10,20 which is selected from the group consisting of the following nucleotide sequences:
  - ACAGCAGATGACATCATT
  - TAATGAAAGAAATGTGCTTA
  - ACACAACTTCAATTAGAAC
- 25 AGTATTAGCAAATGCGG
  - ATGCATATTTTCCGTAA
  - CAGCAGATGACATCATT
  - CATCTAAAGATATATTAAATGGA
  - AGTATTAGCAAATGCGGGTCAC
- 30 CAACACAACTTCAATTAGAA

- **12.** Identification and/or quantification method of a *Staphylococci* species, which may present resistance to antibiotics and which is present in a sample, said method comprising the steps of :
- 5 obtaining a nucleotide sequence from a Staphylococci species present in the sample,
  - amplifying said nucleotide sequence with one or more oligonucleotide(s) according to the claims 1 to 8, and
- identifying and possibly quantifying the specific
  10 Staphylococci species: '

15

- amplified hybridisation of the reverse - by more with one or nucleotide sequence oligonucleotide(s) according to the claims 9 to 11 (are) specific of said Staphylococci is species and is (are) immobilised on a solid support or
- by a comparative measure of the length of the amplified nucleotide sequence.
- of Staphylococci species comprising the oligonucleotide according to any of the preceding claims 1 to 11 and possibly all the media necessary for the identification of an amplified sequence of said Staphylococci species through any one of the methods selected from the group consisting of in situ hybridisation, hybridisation on a solid support, in solution on dot blot, Northern blot, Southern blot, probe hybridisation by the use of an isotopic or non-isotopic label, genetic amplification or a mixture thereof.
- 14. femA genetic sequence which presents more
  30 than 90% homology with a nucleotide or amino acid sequence selected from the group consisting of the nucleotide or

WO 99/16780 PCT/BE98/00141

amino acid sequences represented in the enclosed Fig. 6 to 13.

- 15. Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 6.
- 5 16. Genetic sequence according to claim 14, being the amino acid sequence of Fig. 6.
  - 17. Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 7.
- 18. Genetic sequence according to claim 14,
  10 being the amino acid sequence, of Fig. 7.
  - 19. Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 8.
  - 20. Genetic sequence according to claim 14, being the amino acid sequence of Fig. 8.
- 21. Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 9.
  - 22. Genetic sequence according to claim 14, being the amino acid sequence of Fig. 9.
- 23. Genetic sequence according to claim 14,20 being the nucleotide sequence of Fig. 10.
  - 24. Genetic sequence according to claim 14, being the amino acid sequence of Fig. 10.
  - 25. Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 11.
- 26. Genetic sequence according to claim 14, being the amino acid sequence of Fig. 11.
  - 27. Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 12.
- 28. Genetic sequence according to claim 14,
  30 being the amino acid sequence of Fig. 12.
  - 29.Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 13.

WO 99/16780 PCT/BE98/00141

26

30. Genetic sequence according to claim 14, being the amino acid sequence of Fig. 13.